<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616108</url>
  </required_header>
  <id_info>
    <org_study_id>BPX-STRAB</org_study_id>
    <nct_id>NCT01616108</nct_id>
  </id_info>
  <brief_title>Bupivacaine Injection of Eye Muscles to Treat Strabismus</brief_title>
  <official_title>Bupivacaine Injection of Eye Muscles to Treat Strabismus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith-Kettlewell Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eidactics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sutter Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Strabismus Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Smith-Kettlewell Eye Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to determine if bupivacaine injection of eye muscles can make them stronger
      and stiffer, and thereby correct the position of eyes that are turned in or mis-aligned, a
      condition generally termed strabismus. It seeks further to find out the different effects of
      various concentrations or formulations of bupivacaine, and whether addition of Botox to other
      eye muscles can add to the effect of bupivacaine and enhance the correction of strabismus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for inclusion in the study will be age 8 to 95 years and have an eye
      deviation (strabismus) that is potentially subject to surgical correction.

      The eye alignment will be measured. The eye muscles will be measured by MRI. The eye will be
      anesthetized by eye drops. One or more eye muscles will be injected with bupivacaine. BotoxÂ®
      will be injected into the antagonist muscle in some cases to increase the effect of the
      bupivacaine.

      Data on the strabismus deviation, any side effects of the drug injection, and the eye muscles
      as measured by MRI, will be recorded at intervals after injection. These data will be
      compared with the like measurements taken before injection.

      The primary outcome will be the eye alignment change at 180 days. A secondary outcome will be
      the change in muscle size, strength, or stiffness.

      For large strabismus deviations not fully corrected by a first injection, a second injection
      can be made. Follow-up alignment and muscle measurements will be as for the initial
      injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eye alignment</measure>
    <time_frame>6 months after injection</time_frame>
    <description>Alignment of the two eyes as measured by prism cover test or other applicable test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage correction of the pre-treatment eye deviation</measure>
    <time_frame>6 months after injection treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Strabismus</condition>
  <condition>Esotropia</condition>
  <condition>Exotropia</condition>
  <condition>Graves Disease</condition>
  <condition>Nystagmus</condition>
  <arm_group>
    <arm_group_label>Bupivacaine Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.</description>
    <arm_group_label>Bupivacaine Injection</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical pattern of strabismus of 5 prism diopters or more

        Exclusion Criteria:

          -  Paralytic strabismus

          -  Active eye infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan B Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strabismus Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel M Miller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eidactics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan B Scott, MD</last_name>
    <phone>415 923 3120</phone>
    <email>abs@srfsf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel M Miller, PhD</last_name>
    <phone>858 220 2226</phone>
    <email>kkd@srfsf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Strabismus Research Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALAN B SCOTT, MD</last_name>
      <phone>415-509-2122</phone>
      <email>abs@srfsf.org</email>
    </contact>
    <investigator>
      <last_name>ALAN B SCOTT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.srfsf.org</url>
    <description>Homepage for The Strabismus Research Foundation.</description>
  </link>
  <link>
    <url>http://www.eidactics.com/projects/bpx-treatment</url>
    <description>Collaboration with Eidactics on the bupivacaine treatment of strabismus.</description>
  </link>
  <reference>
    <citation>Miller JM, Scott AB, Danh KK, Strasser D, Sane M. Bupivacaine injection remodels extraocular muscles and corrects comitant strabismus. Ophthalmology. 2013 Dec;120(12):2733-40. doi: 10.1016/j.ophtha.2013.06.003. Epub 2013 Aug 2.</citation>
    <PMID>23916485</PMID>
  </reference>
  <reference>
    <citation>Scott AB, Miller JM, Shieh KR. Bupivacaine injection of the lateral rectus muscle to treat esotropia. J AAPOS. 2009 Apr;13(2):119-22. doi: 10.1016/j.jaapos.2008.10.016.</citation>
    <PMID>19393509</PMID>
  </reference>
  <reference>
    <citation>Scott AB, Alexander DE, Miller JM. Bupivacaine injection of eye muscles to treat strabismus. Br J Ophthalmol. 2007 Feb;91(2):146-8. Epub 2006 Nov 29.</citation>
    <PMID>17135337</PMID>
  </reference>
  <reference>
    <citation>Debert I, Miller JM, Danh KK, Scott AB. Pharmacologic injection treatment of comitant strabismus. J AAPOS. 2016 Apr;20(2):106-111.e2. doi: 10.1016/j.jaapos.2015.11.011.</citation>
    <PMID>27079589</PMID>
  </reference>
  <results_reference>
    <citation>Scott AB, Miller JM, Shieh KR. Treating strabismus by injecting the agonist muscle with bupivacaine and the antagonist with botulinum toxin. Trans Am Ophthalmol Soc. 2009 Dec;107:104-9.</citation>
    <PMID>20126486</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2012</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Smith-Kettlewell Eye Research Institute</investigator_affiliation>
    <investigator_full_name>Alan B. Scott</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>strabismus</keyword>
  <keyword>diplopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Exotropia</mesh_term>
    <mesh_term>Esotropia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

